Linked Data API

Show Search Form

Search Results

1128437
registered interest false more like this
date less than 2019-05-23more like thismore than 2019-05-23
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading NHS: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether (a) NICE and (b) NHS England take into account the availability of medicines under the Early Access to Medicines Scheme when assessing those same medicines for approval as new medicines. more like this
tabling member constituency Bolton West more like this
tabling member printed
Chris Green more like this
uin 257759 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-06-07more like thismore than 2019-06-07
answer text <p>The National Institute for Health and Care Excellence takes into account the availability of medicines through the Early Access to Medicines Scheme (EAMS) in terms of scheduling its assessments, however the process followed in assessing the technology is the same as for non-EAMS technologies.</p> more like this
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
question first answered
less than 2019-06-07T14:54:05.017Zmore like thismore than 2019-06-07T14:54:05.017Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
4398
label Biography information for Chris Green more like this